Aptahem AB (publ) (APTA.ST)
SEK 1.8
(3.15%)
SEK 1.8
(3.15%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 10.01 Million SEK | 10.44% |
| 2022 | 9.06 Million SEK | -68.17% |
| 2021 | 28.48 Million SEK | 17.69% |
| 2020 | 24.2 Million SEK | 38.9% |
| 2019 | 17.42 Million SEK | 1742349300.0% |
| 2018 | 1.00 SEK | 125.0% |
| 2017 | -4.00 SEK | -300.0% |
| 2016 | -1.00 SEK | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 2.6 Million SEK | -16.88% |
| 2024 Q1 | 3.13 Million SEK | -4.92% |
| 2023 FY | 10.01 Million SEK | 10.44% |
| 2023 Q2 | 2.74 Million SEK | 13.76% |
| 2023 Q3 | 1.55 Million SEK | -43.28% |
| 2023 Q4 | 3.29 Million SEK | 111.62% |
| 2023 Q1 | 2.41 Million SEK | -20.49% |
| 2022 Q2 | 2.11 Million SEK | 11.07% |
| 2022 FY | 9.06 Million SEK | -68.17% |
| 2022 Q4 | 3.03 Million SEK | 51.15% |
| 2022 Q3 | 2 Million SEK | -5.15% |
| 2022 Q1 | 1.9 Million SEK | -69.65% |
| 2021 Q3 | 5.17 Million SEK | 9.4% |
| 2021 FY | 28.48 Million SEK | 17.69% |
| 2021 Q2 | 4.73 Million SEK | 0.0% |
| 2021 Q4 | 6.28 Million SEK | 21.28% |
| 2020 FY | 24.2 Million SEK | 38.9% |
| 2019 FY | 17.42 Million SEK | 1742349300.0% |
| 2018 FY | 1.00 SEK | 125.0% |
| 2017 FY | -4.00 SEK | -300.0% |
| 2016 FY | -1.00 SEK | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Calliditas Therapeutics AB (publ) | 1.51 Billion SEK | 99.339% |
| Camurus AB (publ) | 1.05 Billion SEK | 99.055% |
| Mendus AB (publ) | 129.13 Million SEK | 92.246% |
| Lipum AB (publ) | 37.3 Million SEK | 73.161% |
| NextCell Pharma AB | -576.01 Thousand SEK | 1838.301% |
| Simris Alg AB (publ) | 38.64 Million SEK | 74.088% |
| Elicera Therapeutics AB (publ) | 28.32 Million SEK | 64.651% |
| Active Biotech AB (publ) | 44.8 Million SEK | 77.654% |
| Amniotics AB (publ) | 29.07 Million SEK | 65.558% |
| Asarina Pharma AB (publ) | 14.65 Million SEK | 31.666% |
| BioArctic AB (publ) | 89.62 Million SEK | 88.828% |
| Cantargia AB (publ) | 290.01 Million SEK | 96.547% |
| Scandinavian ChemoTech AB (publ) | 21.89 Million SEK | 54.268% |
| CombiGene AB (publ) | 44.14 Million SEK | 77.318% |
| Diamyd Medical AB (publ) | 142.98 Million SEK | 92.997% |
| Genovis AB (publ.) | 88.19 Million SEK | 88.647% |
| Guard Therapeutics International AB (publ) | 115.07 Million SEK | 91.299% |
| Isofol Medical AB (publ) | 7.26 Million SEK | -37.768% |
| Intervacc AB (publ) | 79.78 Million SEK | 87.45% |
| Kancera AB (publ) | 63.07 Million SEK | 84.126% |
| Karolinska Development AB (publ) | 5.51 Million SEK | -81.427% |
| LIDDS AB (publ) | 27.75 Million SEK | 63.92% |
| Lipigon Pharmaceuticals AB (publ) | 7.25 Million SEK | -38.033% |
| Magle Chemoswed Holding AB (publ) | 135.91 Million SEK | 92.633% |
| OncoZenge AB (publ) | 15.9 Million SEK | 37.045% |
| Saniona AB (publ) | 1.07 Million SEK | -829.707% |
| Vicore Pharma Holding AB (publ) | 321.5 Million SEK | 96.886% |
| Xbrane Biopharma AB (publ) | 357.62 Million SEK | 97.2% |
| Xintela AB (publ) | 57.31 Million SEK | 82.53% |
| Xspray Pharma AB (publ) | 181.73 Million SEK | 94.49% |
| Ziccum AB (publ) | 27.87 Million SEK | 64.083% |
| Modus Therapeutics Holding AB (publ) | 16.4 Million SEK | 38.949% |
| Alligator Bioscience AB (publ) | 307.09 Million SEK | 96.739% |
| Sprint Bioscience AB (publ) | 42.63 Million SEK | 76.513% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 17.68 Million SEK | 43.375% |
| Corline Biomedical AB | 30.16 Million SEK | 66.809% |
| IRLAB Therapeutics AB (publ) | 58.03 Million SEK | 82.746% |
| Bio-Works Technologies AB (publ) | 83.16 Million SEK | 87.961% |
| Infant Bacterial Therapeutics AB (publ) | 134.69 Million SEK | 92.566% |
| Fluicell AB (publ) | 28.61 Million SEK | 65.011% |
| Biovica International AB (publ) | 133.72 Million SEK | 92.512% |
| Spago Nanomedical AB (publ) | 19.79 Million SEK | 49.404% |
| AcouSort AB (publ) | 25.87 Million SEK | 61.304% |
| Abliva AB (publ) | 27.86 Million SEK | 64.068% |
| Egetis Therapeutics AB (publ) | 193.5 Million SEK | 94.825% |
| 2cureX AB (publ) | 36.51 Million SEK | 72.581% |
| I-Tech AB | 40.14 Million SEK | 75.06% |
| Hansa Biopharma AB (publ) | 859.44 Million SEK | 98.835% |
| Cyxone AB (publ) | 28.21 Million SEK | 64.511% |
| ExpreS2ion Biotech Holding AB (publ) | 109.36 Million SEK | 90.845% |
| Biosergen AB | 26.8 Million SEK | 62.651% |
| Nanologica AB (publ) | 69.88 Million SEK | 85.673% |
| SynAct Pharma AB | 224.49 Million SEK | 95.54% |
| Annexin Pharmaceuticals AB (publ) | 44.17 Million SEK | 77.334% |
| BioInvent International AB (publ) | 441.4 Million SEK | 97.732% |
| Stayble Therapeutics AB (publ) | 23.95 Million SEK | 58.2% |
| Alzinova AB (publ) | 36.39 Million SEK | 72.489% |
| Oncopeptides AB (publ) | 289.74 Million SEK | 96.544% |
| Pila Pharma AB (publ) | 7.85 Million SEK | -27.452% |
| Ascelia Pharma AB (publ) | 110.91 Million SEK | 90.972% |
| Diagonal Bio AB (publ) | 14.7 Million SEK | 31.885% |